Overview of Notolac

Property	Description
Active Ingredient	Ketorolac Trometamol
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Form	Tablet, Injectable Solution, Ophthalmic Solution
General Purpose	Relief from moderate-to-severe pain
Origin	Synthetic, Non-opioid

What Type of Medicine is Notolac?

Notolac is classified as a potent, synthetic prescription medicine belonging to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class and is clinically recognized for its analgesic efficacy. Its fundamental purpose is to relieve pain and reduce inflammation. Notolac's identity as a potent analgesic sets it apart from typical over-the-counter pain relievers. The active ingredient, Ketorolac Trometamol, is an agent used primarily for its anti-inflammatory effects. Because it acts peripherally on the pain site rather than centrally on the brain, it is not a narcotic, offering effective pain management without the dependency risks associated with opioid medications.

Composition and Available Forms

The essence of the drug lies in its single active ingredient, Ketorolac Trometamol, which is chemically defined as the tromethamine salt of ketorolac. This compound is a synthetic member of the acetic acid derivative group of NSAIDs. Notolac is distinguished within the market by the range of dosage forms available, designed to address varied patient needs: the oral tablet for systemic use, an injectable solution for parenteral administration (given into the muscle or vein), and specialized preparations such as the ophthalmic solution (eye drops) for localized treatment. This versatility allows its use across different healthcare settings, such as managing acute post-operative pain or treating specific ocular inflammation.

General Therapeutic Purpose and Action

The general therapeutic purpose of Notolac is to deliver rapid and decisive relief by targeting the chemical pathways responsible for generating pain signals. This potent NSAID interferes with the body's processes that produce inflammatory mediators, notably prostaglandins. Ketorolac's inhibition of cyclooxygenase enzymes directly underpins its analgesic effect. This means the medicine works by stopping the production of the chemicals that signal pain. The resulting effect is a powerful tool for the acute, short-term management of discomfort stemming from injury or medical procedures.

Therapeutic Uses of Notolac

The primary therapeutic use of Notolac (Ketorolac) is to provide symptomatic relief in situations involving certain distressing symptoms, which contributes to improved comfort during periods of heightened symptoms. The medication is utilized for managing acute episodes where pain is moderately severe, generally following a surgical procedure or serious injury. This provides supportive relief that helps ease the overall symptom burden of intense physical discomfort and inflammation.

Key Symptom Domains and Benefits

This medication is generally applied in addressing symptom clusters that may become intense or disruptive, such as the acute pain associated with discomfort after an operation, certain forms of musculoskeletal trauma, and specific episodes of menstrual cramping (dysmenorrhea). In its topical form, it is relevant for easing symptoms linked to post-cataract surgery inflammation and temporary ocular itching.

“It is commonly used when short-term symptomatic assistance is needed.”

This application is relevant when supportive symptom management is appropriate because symptoms create noticeable physiological strain, which may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Pain

Focus: Moderate-to-severe discomfort after surgery or injury.
Benefit: Provides supportive symptomatic relief that provides support that helps ease the overall symptom burden consistent with non-opioid supportive care.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Notolac?

Notolac (Ketorolac Trometamol) is a potent medicine restricted to specific populations based on regulatory labeling. Use is generally indicated for adult patients 16 years of age and older for short-term management (typically limited to five days) of acute pain.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for several high-risk groups. Patients must not use Notolac if they have active peptic ulcer disease or a history of recent GI bleeding or perforation. It is also prohibited for those with advanced renal impairment, severe heart failure, or conditions posing a high risk of bleeding, such as confirmed cerebrovascular bleeding. Individuals with a known hypersensitivity to aspirin or other NSAIDs are also excluded. Furthermore, use is contraindicated for peri-operative pain in CABG surgery and as a prophylactic analgesic before major surgery.

Population Restrictions

Pediatric Patients: Use is not indicated or not established for children under 16 years of age.
Older Adults (ge 65): This group is eligible but requires mandatory reduced maximum daily dosages due to an increased risk of serious adverse events.
Pregnancy and Lactation: Notolac is contraindicated during the third trimester of pregnancy (due to risk to the fetus) and is contraindicated in nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Notolac's official regulatory profile identifies several clinically significant interactions, categorizing them primarily by the increased risk of adverse effects or significant alterations in drug exposure.

Contraindicated Combinations

Co-administration is strictly contraindicated with several substance classes due to increased safety risks. These include other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and analgesic doses of Aspirin (ASA), which heighten the risk of serious gastrointestinal events. Additionally, co-administration is forbidden with anticoagulants (such as Warfarin) and Pentoxifylline due to an increased risk of bleeding. The combination with Probenecid and Lithium salts is also contraindicated, as these agents substantially increase Notolac's or Lithium's plasma concentrations.

Significant Interaction Categories

Interacting Category	Interaction Outcome (As documented)
Antihypertensive Agents (e.g., ACE inhibitors, ARBs)	Potential reduction in antihypertensive effect due to prostaglandin inhibition.
Diuretics (e.g., Furosemide)	Reduced natriuretic (water-losing) effect, requiring patient monitoring.
Methotrexate	Risk of enhanced Methotrexate toxicity due to decreased renal clearance.
Alcohol	Increased additive risk of gastrointestinal irritation and bleeding.

Population Considerations

The official labeling notes that in elderly patients or individuals who are volume-depleted, the co-administration of Notolac with ACE Inhibitors or Angiotensin Receptor Blockers (ARBs) significantly increases the risk of impaired renal function.

Mechanism of Action

Molecular Targeting of the Cyclooxygenase (COX) System

The mechanism of action for Ketorolac (Notolac) is defined by the non-selective inhibition of the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. The drug's active S-enantiomer blocks the catalytic active site of these enzymes, halting the enzymatic conversion of arachidonic acid into chemical mediators, specifically prostaglandins. This molecular interference occurs at the earliest step of the Arachidonic Acid Cascade.

⬇️ Attenuation of Peripheral Signaling

By preventing prostaglandin formation, the drug suppresses these mediators which are critical for sensitizing peripheral nociceptors (pain receptors). The resulting drop in mediator concentration at the tissue level attenuates peripheral nociceptive signaling and results in reduced local nociceptor sensitization. This also decreases prostaglandin-mediated vascular component activity.

Functional Constraint of Non-Selective Action

This mechanism is constrained by its non-selective action, which includes the inhibition of constitutive COX-1. This functional constraint inherently modulates homeostatic pathways, such as those involved in gastric mucosal maintenance and renal blood flow regulation, thereby establishing a physiological limit on the extent of mechanism engagement.

Dosage and Administration Information

Administration and Dosing of Notolac

The use of Notolac (Ketorolac Trometamol) is governed by strict guidelines regarding its route, duration, and dose. It is designated for short-term use only and not for chronic pain management. The total combined duration of systemic treatment (IM, IV, and oral) must not exceed 5 days.

Routes and Administration

Notolac is available for systemic administration via Intramuscular (IM) injection, Intravenous (IV) bolus, and Oral tablet. The injectable solution is typically used to initiate therapy, while the oral tablet is only indicated for continuation treatment following IV or IM dosing.

IV Bolus: Must be administered slowly, over no less than 15 seconds.
IM Injection: Must be administered slowly and deeply into the muscle.

Standard Dosing and Frequency

Dosing regimens are based on the route and patient weight, and are designed to achieve the lowest effective dose for the shortest duration necessary. The following maximums apply to most adults (under 65 years, ge 50 kg body weight):

Route	Standard Regimen	Maximum Daily Dose
IM/IV Multiple-Dose	30 mg IM/IV every 6 hours	120 mg
Oral Continuation	10 mg every 4 to 6 hours	40 mg

Population-Specific Use

Specific dosage reductions are mandated for patients who may clear the drug more slowly or be more sensitive to dose-related effects.

Older Adults (ge 65 years): The maximum total daily dose for IM/IV use must not exceed 60 mg/day.
Low Body Weight: For patients weighing less than 50 kg (110 lbs), the maximum total daily dose for IM/IV use must not exceed 60 mg/day.
Renal Impairment: Dosing must be reduced, and the maximum total daily dose for IM/IV use must not exceed 60 mg/day.

Recent Clinical Evidence

Evidence for Use in Moderate-to-Severe Acute Systemic Pain

The research base for Notolac's use in systemic pain, often requiring the injectable or oral form, comes mainly from short-term, controlled clinical trials. These studies were used in research exploring how symptoms change over time in adult patients recovering from procedures like general or orthopedic surgery. Researchers primarily focused on outcomes related to physical discomfort, such as the reduction in pain intensity scores and the consumption of rescue opioid medication (Postoperative Opioid Consumption).

The trials reported patterns where pain scores were observed to change during the study period. Some studies described patterns related to the patient's need for supplemental opioid medication in the study group. Follow-up durations were strictly limited to a maximum of 5 days, and data for long-term outcomes for chronic pain conditions are not fully established.

Evidence for Use in Ocular Inflammation and Pain

The evidence supporting the use of Notolac as an ophthalmic solution is based on dedicated Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating symptoms, mainly for patients recovering from specific eye surgeries, such as cataract surgery. Research examined outcomes related to inflammatory or irritative states in the eye.

Researchers monitored patient-reported outcomes describing perceived discomfort (ocular pain scores) and objective inflammation metrics. Studies reported measurable changes in ocular pain scores. Data described changes in inflammation metrics, which researchers monitored over a period of up to several weeks post-surgery. Comparative evidence is also lacking in some areas, as subgroup findings remain uncertain when trying to establish clear differences against all other topical anti-inflammatory drops available.

Research Gaps and Uncertainties

A significant gap is the lack of long-term data for any indication, reinforcing the medicine’s identity as an acute, short-term treatment. For systemic use, the data for maintenance or durability of response over months or years remain insufficient. While studies have included older adults (65 years and over), the sample sizes for this specific subgroup were often limited, meaning that evidence for this specific subgroup remains insufficient. More research is needed to fully characterize the specific profiles in complex or high-risk patient subgroups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Notolac (FAQ)

Q: What is the role of Notolac in treating my condition?

According to official product information, Notolac is classified as a non-steroidal anti-inflammatory drug (NSAID). Regulatory documents describe its intended use as relieving inflammation and pain. It is indicated for the acute (short-term) management of moderate to severe pain, often following surgery or for certain inflammatory conditions like arthritis.

Q: How long does it take for Notolac to start working?

Official information indicates that Notolac is generally rapidly and completely absorbed following administration. This rapid absorption suggests that the onset of pain relief can occur relatively soon after administration. Due to its pharmacokinetic properties, some patients may notice the effects of Notolac shortly after taking a dose.

Q: What should I do if I miss a dose of Notolac?

The official instructions indicate that a missed dose should typically be skipped, and the patient should simply continue with the next regularly scheduled dose. It is generally advised not to take a double dose to compensate for the one that was missed. The product information emphasizes the importance of following the dosing guidance provided by a healthcare professional.

Q: Is it safe to drive or operate machinery after taking Notolac?

According to the official product information, Notolac may potentially cause adverse effects such as dizziness, drowsiness, or visual disturbances. Patients who experience these side effects are typically advised to use caution. If these effects occur, it is generally recommended to avoid driving or operating dangerous machinery.

Q: Can Notolac be used in children?

Official regulatory documents state that Notolac is not approved for use in children under 16 years of age. Its use is limited to adult patients (age 16 and older) for specific indications listed on the product label. Alternative treatments are usually required for pediatric patients.

Q: Is Notolac the same as an opioid painkiller?

No, according to its official classification, Notolac is an NSAID (non-steroidal anti-inflammatory drug). This medication belongs to a different class than opioid painkillers. NSAIDs function by reducing the body's production of prostaglandins, which are compounds responsible for triggering inflammation and pain.

How should Notolac be stored and disposed of?

Storage and Disposal of Notolac (Ketorolac Tromethamine)

Notolac must be stored according to specific regulatory requirements to maintain product integrity and stability. The medication should be kept at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F).

Storage Requirement	Condition
Temperature	Do not freeze or store above 30 C.
Protection	Protect from light, excess heat, and moisture.
Container	Keep in the original, tightly closed container.
Safety	Keep the medicine out of reach of children.

Disposal of unused or expired Notolac must adhere to Federal, State, and local procedures. Unneeded tablets should be mixed with an undesirable substance, sealed in a container or bag, and placed in household trash, avoiding environmental release.

Notolac